Lates News

Each economy AI express, open source securities on April 28 released a research report that gave Jichuan Pharmaceutical (600566.SH) a buy rating. The main reasons for the rating include: 1) The revenue from clearing heat and detoxification, digestion, and pediatric departments has declined, and the gross profit margin has come under slight pressure; 2) "Research and development + BD" enriching pipeline layout, enhancing long-term competitive strength. (Daily Economic News)